Biomedical subjects

A V Streliaeva

Publications and source records attributed to A V Streliaeva.

10 recordsLinked to original sources

PubMed2002

[Mediastinal echinococcosis].

Among 29,875 autopsies 59 cases of mediastinal echinococcosis were revealed. Among 4178 patients with thoracic echinococcosis 55 patients had mediastinal echinococcosis. All the patients were operated, most of them underwent ideal ecinococcectomy. Intraoperative prophylaxis of echinococcosis was performed: plearal cavity was treated by low-frequency ultrasound and glycerin. 7 examined patients demonstrated reduction of immune and phagocytosis indices in blood (DC3+, CD4+, CD8+, CD16+, CD21+). Increase of immunoglobulines A, M, G and circulating immune complexes was revealed. Reactions of scolexprecipitation and lymphocytes antigen-fixing were positive.

Antigens, CD↗

PubMed2000

[Treatment of hydatid cysts' residual cavities (experimental and clinical study)].

Experimental series of 60 cotton rats and 150 white mice infected with echinococcus showed that 80-100% glycerin and 3% peroxide solution were effective scolicidal solutions for inactivation of the parasite. 344 patients have been operated on for hydatid disease with inactivation of the parasite by means of these scolicidal solutions. Glycerin during the surgical management of the hydatid cysts is effective and harmless in uncomplicated hydatid liver disease and any hydatid pulmonary cysts. Glycerin is contraindicated in complicated hydatid liver disease because of immunity disturbance. In complicated hydatid liver disease management of the hydatid cysts by 3% peroxide is effective and harmless. It is necessary to correct the hydatid liver disease patients' immunity in the preoperative and postoperative periods. Tactivin and antiechinococcus drug SK-1 are effective immunomodulators in hydatid liver disease.

Adjuvants, Immunologic↗

PubMedDate not supplied

[Experimentally inoculated human echinococcosis in piglets and a trial of the therapeutic preparation SK-1].

Experiments were made on 26-month-old piglets divided into 4 groups: Groups 1 and 4 included 5 piglets and Groups 2 and 3 comprised 8 animals. The piglets from Groups 1, 2, and 3 were peritoneally inoculated with 5000 protoscolices and acephalocysts of Echinococcus from patients with echinococcosis who had been operated on. On postinoculation day 60, Group 1 piglets were killed to measure the baseline weight of parasitic larvocysts (PL) developed by that time. On postinoculation day 61, Group 3 piglets continuously received feed in combination with CK-1 within 3 weeks. The mean daily doses of the agent were 0.05, 0.10, 0.25 g/kg, respectively. On day 91 following inoculation, all the animals were killed and dissected. The studies were made by using the procedures and formulas [9]. The growth suppression index for PL was 94.50, 92.39, and 96 for Groups 1, 2, and 3, respectively. Significant destruction of embryonic elements was revealed in 75-85% of PL in each treated animals. There was a tendency for blood indices to become normal in the treated animals. The acute toxicity of CK-1 was examined in outbred white mice, albino rats, chickens, piglets. The maximum non-lethal dose of CK-1 was 19 g/kg for white mice. The agent showed a low toxicity.

Animals↗

PubMedDate not supplied

[An improvement in a new method for the surgical treatment of echinococcosis].

Parasitic cysts were intraoperatively treated with glycerol in 179 patients with echinococcosis at various sites and 3% hydrogen peroxide in 165 patients with hepatic echinococcosis. Experiments on 60 cotton rats experimentally infected with Echinococcus alveolaris and 156 albino mice with E. granulosus provided evidence for the surgical use of 80-100% glycerol or 3% hydrogen peroxide to treat the cysts. Intraoperative glycerol treatment of cysts in patients with complicated hepatic echinococcosis fails to normalize amino acid metabolism, as well as immunity even a year postoperatively. The glycerol method has no contraindications for pulmonary and hepatic echinococcosis. Hydrogen peroxide has a damaging effect on all germinal elements of both E. alveolaris and E. granulosus. The authors recommend that 3% hydrogen peroxide should be intraoperatively used for treatment of cysts. After surgery, there is a tendency for amino acid metabolism to become normal in such patients.

Amino Acids↗

PubMedDate not supplied

[A trial of the preparation Cheblin-SK-1 in models of nematodiases].

A kerosene milky-stage walnut (Juglans spp.) extract, a folk medication, has come into wide use in the past 30 years. The drug CK-I was prepared on a scientific basis. Its acute toxicity and toxicological profile were studied on albino mice and rats, chickens, chicken embryos, piglets. The maximum non-lethal dose of CK-I was 19 g/kg for albino mice and 21 g/kg for albino rats. The drug can be classified as i.v. hazard class. The anthelmintic effects of CK-I were examined in mice with cyphaciasis and in chickens with ascariasis and heterakiasis. In murine cyphaciasis, CK-I given in a dose of 75 mg/kg to albino mice provided 100% efficiency. Its doses of 800 and 1000 mg/kg were required to achieve this effect in chick ascariasis and heterakiasis, respectively.

Animals↗

PubMedDate not supplied

[Homeopathic preparation Cheblin-CK-1 in the pathogenetic therapy of echinococcosis].

This study was experimental and clinical. The experiments were made on 80 cotton rats. The clinical study covered 289 patients operated on for echinococcosis. Earlier studies indicated that echinococcosis is accompanied by secondary immunodeficiency and amino acid metabolic disorders. The homeopathic drug Cheblin-CK-1 used normalized amino acid metabolism 40 days after treatment in these patients. The same properties were displayed by homeopathic drugs.

Adjuvants, Immunologic↗

PubMedDate not supplied

[Testing CK group preparations in hymenolepiasis in white mice].

The drugs CK-1 and CK-2 are a kerosene milky-stage walnut (Juglans spp.) extract. The drugs CK-3, CK-4, and CK-5 are derived from monkshood (Aconitum) roots, garlic (Allium sativum), and Ferula, respectively. Albino mice were infected with hymenolepiasis by the procedure of B.A. Astafyev et al. (1989). The mice were aged 3 weeks, weighed 7-8 g, and spontaneous invasion-free. The doses of 25 to 100 mg/kg were tested. The antihelminthic effects of the extragent of the drugs--aircraft kerosine purified by the authors' procedure--were additionally examined. The purified aircraft kerosine was found to have moderate antihelminthic effects, but failed to provide 100% antihelminthic activity when given even in very high doses (500 mg/kg or more). The drug CK-1, 100 mg/kg, completely eliminated hymenolepiasis in the experimental animals. Other drugs CK-3, CK-4, and CK-5 used in doses of 100 mg/kg body weight failed to provide 100% antihelminthic efficiency.

Animals↗

PubMedDate not supplied

[Immunity induced by immunomodulators during echinococcal immunosuppression].

The echinococcal immunosuppression induced in experimental mice by a human parasite strain is accompanied by immunosuppression, whereby the administration of immunomodulants favors normalization of the cell and humoral immunity chains. Among a series of preparations studied, the best results were obtained for polyoxidonium: in the case of immunosuppression induced by cyclophosphan, polyoxidonium administration led normalization of the cell and humoral immunity and the phagocytosis of neutrophils and macrophages.

Adjuvants, Immunologic↗

PubMedDate not supplied

[Antimicrobial, echinococcidial and immunostimulating properties of the drug Cheblin-SK-1].

The antimicrobial properties of the drug Cheblin-CK-1 (CCK-1) were determined in mice intraabdominally inoculated with Proteus mirabilis-4691 in a dose of 140-200 million daily cultured microbial bodies. Its comparison agent was ampicillin. CCK-1 was found to act as an antibiotic similar to ampicillin in its effects. The antimicrobial activity of CCK-1 against Staphylococcus aureus and Escherichia coli isolated from the contents of echinococcal cysts from patients operated on was also established. Its echinococcidial activity was found in experiments on the cotton rats and piglets inocculated with echinococci. CCK-1 was also tested on volunteers. Before surgery, 186 patients with echinococcosis took the drug and 26 patients with the same disease did not and they served as controls. At first the drug suppressed the growth of parasitic larvocysts with destruction and death of 85-95% of germinal elements of larvocysts and then killed parasites. In patients receiving a complete course of its therapy, protein and amino acid metabolisms restored, followed by immunity recovery.

Animals↗

PubMedDate not supplied

[Experimental echinococcosis and alveococcosis and a trial of the preparation SK-1].

In autobred albino mice, the maximum nonlethal dose of the agent CK-1 was established, which was 19.0 g/kg, the agent was nontoxic. Cotton rats aged 30-45 days were infected by alveococcosis from a donor rat. The methods and formulas developed by Mikhaĭlitsin et al. were used during experiments and investigations. At the beginning of treatment, 5 rats were found to have a great deal of parasitic larvocysts (PL) 10 days after infection. Eight rats formed a control group, 8 were treated with CK-1 in a constantly increasing doses of 0.1, 0.26, and 0.34 g/kg for 3 weeks. Following 40 days of infection, the animals were anesthesized and CK-1 was ascertained to have a high antialveococcal activity: the index of suppressed PL growth was 90.23 to 92.74%. In 14 piglets aged 1 month, infected by echinococcosis strains and treated CK-1 in high doses, was established to cause echinococcal death. In 14 puppies, the agent was highly effective in strobular echinococcosis.

Animals↗